Two Sigma Investments LP Sells 106,788 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Two Sigma Investments LP trimmed its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 14.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 610,996 shares of the medical device company's stock after selling 106,788 shares during the quarter. Two Sigma Investments LP owned about 1.25% of AtriCure worth $18,672,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Johnson Financial Group Inc. increased its position in AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock worth $49,000 after acquiring an additional 1,492 shares during the period. Heck Capital Advisors LLC acquired a new stake in AtriCure during the fourth quarter worth about $60,000. Venturi Wealth Management LLC grew its stake in AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after buying an additional 2,100 shares in the last quarter. KBC Group NV grew its stake in AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after buying an additional 932 shares in the last quarter. Finally, State of Wyoming grew its stake in AtriCure by 21.9% during the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after buying an additional 446 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

AtriCure Price Performance

Shares of ATRC traded down $0.42 during mid-day trading on Wednesday, reaching $33.58. The company had a trading volume of 62,321 shares, compared to its average volume of 612,503. The company's 50 day simple moving average is $32.32 and its 200 day simple moving average is $34.74. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -35.34 and a beta of 1.57.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The company had revenue of $123.62 million for the quarter, compared to the consensus estimate of $122.92 million. During the same period last year, the company posted ($0.28) EPS. The firm's quarterly revenue was up 13.5% compared to the same quarter last year. Analysts expect that AtriCure, Inc. will post -0.6 EPS for the current year.

Insider Buying and Selling

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. UBS Group reduced their price objective on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Needham & Company LLC reduced their price objective on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Stifel Nicolaus increased their price objective on shares of AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. reduced their price objective on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, March 27th. Finally, Oppenheimer increased their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AtriCure has an average rating of "Buy" and a consensus target price of $50.67.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.